Skip to main content

Table 2 Primary and secondary outcomes in the included cohort

From: Renal outcomes according to renal replacement therapy modality and treatment protocol in the ATN and RENAL trials

 

CRRT (n = 2175)

IHD (n = 367)

Unadjusted analysis

Adjusted analysisa

Effect estimate (95% CI)

p value

Effect estimate (95% CI)

p value

Primary outcome

RRT dependence at day 28—no. (%)

320 (14.7)

113 (30.8)

SHR, 0.75 (0.67 to 0.83)

 < 0.001

SHR, 0.96 (0.84 to 1.10)

0.570

 Death before the event

618 (28.4)

95 (25.9)

    

Secondary outcomes

RRT dependence at day 60—no. (%)

145 (6.8)

49 (13.7)

SHR, 0.75 (0.62 to 0.90)

0.002

SHR, 1.04 (0.85 to 1.28)

0.670

 Death before the event

673 (31.3)

109 (30.4)

    

RRT-free days at day 28

0.0 (0.0–22.0)

0.0 (0.0–17.0)

COR, 1.38 (1.11 to 1.71)

0.004

COR, 1.45 (1.12 to 1.88)

0.005

 Mean ± SD

9.1 ± 10.9

7.2 ± 10.2

    

ICU length of stay, days

9.0 (4.0–19.0)

13.0 (7.0–25.0)

SHR, 0.82 (0.72 to 0.94)*

0.003

SHR, 1.03 (0.87 to 1.21)*

0.750

 In survivors

11.0 (6.0–21.0)

13.0 (7.0–25.0)

    

Hospital length of stay, days

19.0 (9.0–36.0)

25.0 (15.0–41.0)

SHR, 0.69 (0.60 to 0.81)*

 < 0.001

SHR, 0.81 (0.68 to 0.97)*

0.025

 In survivors

28.0 (17.0–47.0)

30.0 (18.0–44.0)

    

ICU mortality—no. (%)

848 (39.0)

108 (29.4)

OR, 1.53 (1.21 to 1.95)

 < 0.001

OR, 0.96 (0.71 to 1.29)

0.778

Hospital mortality—no. (%)

1016 (46.7)

121 (33.0)

OR, 1.78 (1.41 to 2.26)

 < 0.001

OR, 1.14 (0.86 to 1.52)

0.361

28-day mortality—no. (%)

875 (40.2)

114 (31.1)

HR, 1.38 (1.13 to 1.68)**

0.001

HR, 0.90 (0.72 to 1.12)**

0.343

60-day mortality—no. (%)

1005 (46.7)

143 (39.4)

HR, 1.28 (1.07 to 1.52)**

0.006

HR, 0.92 (0.75 to 1.13)**

0.434

Sensitivity analysis

Among survivors at the longest follow-up—no. (%)

      

 RRT dependence at day 28

232 (20.9)

90 (40.9)

OR, 0.38 (0.28 to 0.52)

 < 0.001

OR, 0.54 (0.37 to 0.80)

0.002

 RRT dependence at day 60

136 (12.3)

49 (22.6)

OR, 0.48 (0.33 to 0.70)

 < 0.001

OR, 0.76 (0.48 to 1.22)

0.261

  1. Data are median (quartile 25–quartile 75%) or No (%). Percentages may not total 100 because of rounding. Denominators are shown when the overall sample size was not available
  2. CRRT Continuous renal replacement therapy; IHD Intermittent hemodialysis; ICU Intensive care unit; RRT Renal replacement therapy; SHR Sub-distribution hazard ratio; MD Mean difference; RRT Renal replacement therapy; HR Hazard ratio; OR Odds ratio; COR Common odds ratio
  3. aAll models adjusted for age, gender, weight, type of admission (medical, surgical, or other), APACHE III, cardiovascular SOFA, hours between randomization and therapy, use of mechanical ventilation, presence of oliguria, presence of hyperkalemia, presence of sepsis, last bicarbonate, urea and creatinine before randomization, premorbid estimated glomerular filtration rate, and intensity of treatment (as allocated in the original trials)
  4. *ICU and hospital length of stay censored at day 60
  5. **p value for Schoenfeld residual is 0.830 for 28-day mortality and 0.260 for 60-day mortality
Back to article page

Critical Care

ISSN: 1364-8535